Navigation Links
Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant

PITTSBURGH, Feb. 6, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has successfully completed the acquisition of two dermatological products from Valeant Pharmaceuticals. Mylan has acquired the abbreviated new drug application (ANDA) for Clindamycin Phosphate / Benzoyl Peroxide Gel, which is the generic version of Valeant's BenzaClin®. Mylan previously had manufactured and marketed the generic version of this product through a licensing agreement with Valeant. Mylan also has acquired a license to manufacture and market Fluorouracil 5% USP cream as the exclusive authorized generic to Valeant's Efudex®

Mylan Chief Executive Officer Heather Bresch said: "The acquisition of these two products reflects Mylan's continued strategy of creating value through increasing our position in key therapeutic areas and dosage forms, such as dermatological topicals. Further, it allows us to expand our portfolio of difficult-to-manufacture or limited-competition products. We will continue to build on our existing portfolio and capabilities through opportunities such as these."

Clindamycin Phosphate / Benzoyl Peroxide Gel, 1%/5%, which is indicated for the topical treatment of acne vulgaris,[1] had U.S. sales of approximately $205 million for the 12 months ending Dec. 31, 2011, according to IMS Health. Fluorouracil 5% USP cream, is recommended for the topical treatment of multiple actinic or solar keratoses and also indicated for the treatment of superficial basal cell carcinomas when conventional methods are impractical,[2] had U.S. sales of approximately $79 million for the 12 months ending Dec. 31, 2011, according to IMS Health. The terms of Mylan's agreement with Valeant regarding these two products are confidential.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit For more information about generic drugs, please visit

This press release includes statement that may constitute "forward-looking statements" (including with regard to product launches and the company's strategies) as well as other information that is necessarily subject to risks, uncertainties and assumptions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, market acceptance of the company's products, the impact of competition and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.


[1] Clindamycin taken orally or through IV, has been associated with severe colitis, which may result in death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis have been reported with the use of topical and systemic clindamycin. Patients who experience severe diarrhea, severe abdominal cramps, or allergic symptoms, such as severe swelling or shortness of breath, should immediately discontinue use of the product and consult their physician. The product should not be used in patients with a history of Crohn's disease, ulcerative colitis, or antibiotic-associated colitis. It should not be used with other topical acne medication, unless directed by a physician. Common side effects include dry skin, application site reaction, pruritus, peeling, erythema, and sunburn.

[2] Fluorouracil 5% USP cream may cause fetal harm and should not be used in women who are, or may become, pregnant during therapy. It should not be applied to mucous membranes due to the possibility of local inflammation and ulceration. Exposure to UV rays should be minimized during and immediately following treatment. Fluorouracil 5% USP cream should not be used in patients with DPD enzyme deficiency. Common side effects include burning, crusting, allergic contact dermatitis, erosions, erythema, hyperpigmentation, irritation, pain, photosensitivity, pruritus, scarring, rash, soreness and ulceration.

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
(Date:11/25/2015)... November 25, 2015 --> ... sie eine Lizenz für das Patent über eine neue ... und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... ins Leben gerufenen und von Edelris gemeinsam mit seinen ... ein Behandlungsziel für HBV identifiziert, und es wurden neue ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 25, 2015 , ... ... Their Care Plan software creates an agreement between the practice owner and ... including financial, scheduling, monitoring, notification, and projections. Click here to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Charitable giving is at its peak during ... the last five weeks of the year totalling over $358 billion in 2014. ... the nation’s charities with those individuals who want to “give back” during the holidays. ...
(Date:11/24/2015)... ... 2015 , ... The hospitals and health systems on this ... care. They have received recognition for excellence from various reputable organizations in areas ... Hospital Review selected hospitals for inclusion based on national rankings and awards from ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
(Date:11/24/2015)... ... , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse located ... the staff members at their recovery center. The videos highlight some of the various ... the things that make their recovery program so unique. , “Making the decision to ...
Breaking Medicine News(10 mins):